RTM receives marketing authorisation for Fludeoxyglucose (18F)

We are happy to announce that RTM has received marketing authorization for ¹⁸F-FDG of 17 July 2018.

Fludeoxyglucose (¹⁸F) RTM 200 MBq/ml, solution for injection will become commercially available in The Netherlands in October, with roll-out to Belgium and Germany planned in 2019.

RTM receives marketing authorisation for Fludeoxyglucose (18F)

Other news

18F-FDOPA now available

18F-FDOPA now available

Fluorodopa (18F) is now available for clinical studies and - with doctor's certificate - for routine...

RTM supports Citryll’s imaging trial of [89Zr]Zr-DFO-CIT-013

Radboud Translational Medicine (RTM) is proud to announce its role as manufacturing partner for the...

First liver cancer patient treated with microspheres irradiated in TU Delft

First liver cancer patient treated with microspheres irradiated in TU Delft

Radboud Translational Medicine will perform the dispensing of below product. The production and dis...

LinkedIn post Isologic goes electric

LinkedIn post Isologic goes electric

🔌Isologic Goes Electric! We are excited to announce the expansion of our electric fleet with the a...

Interested in a collaboration?

Contact us to discuss the possibilities.